Balanced news tone
News Sentiment
HLUN-A sentiment intelligence
H. Lundbeck A/S news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
15 relevant articles
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+0.1% over one week, +2.5% over four weeks, trend active, and near fair-value range.
H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
80/100 classification
One-week reaction
0.1%
Price digesting
Trend fit
Trend active
2.5% over four weeks
Fair value
17.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
12
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
simplywall.st
Direct company coverage
H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 14:09
- Source
- simplywall.st
marketscreener.com
Direct company coverage
Nordea raises target price for Lundbeck to DKK60 (57), reiterates buy rating
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 18 Jun 2026 05:41
- Source
- marketscreener.com
Seeking Alpha
Direct company coverage
Lundbeck reports early success for experimental Cushing's disease treatment (HLBBF:OTCMKTS)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jun 2026 20:24
- Source
- Seeking Alpha
Seeking Alpha
Direct company coverage
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment - Slideshow (OTCMKTS:HLBBF) 2026-06-06
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jun 2026 07:00
- Source
- Seeking Alpha
marketscreener.com
Direct company coverage
H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 13 May 2026 07:00
- Source
- marketscreener.com
The Pharma Letter
Direct company coverage
Lundbeck shares slip on pessimistic earnings outlook
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Feb 2026 08:00
- Source
- The Pharma Letter
simplywall.st
Direct company coverage
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 14 Jan 2026 08:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Is Lundbeck Still Attractive After 12.6% Monthly Surge and Positive Neurology Pipeline Updates?
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 23 Sep 2025 07:00
- Source
- simplywall.st
marketscreener.com
Direct company coverage
H. Lundbeck A/S : Lundbeck
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Nov 2024 08:00
- Source
- marketscreener.com
European Biotechnology Magazine
Direct company coverage
Lundbeck to take over Longboard Pharma in US$2.6bn transaction
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Oct 2024 07:00
- Source
- European Biotechnology Magazine
Reuters
Direct company coverage
Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Oct 2024 07:00
- Source
- Reuters
Business Wire
Direct company coverage
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Oct 2024 07:00
- Source
- Business Wire
MedCity News
Direct company coverage
Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Sep 2019 07:00
- Source
- MedCity News
GlobeNewswire
Direct company coverage
Lundbeck to acquire Alder BioPharmaceuticals – a company
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Sep 2019 07:00
- Source
- GlobeNewswire
BioSpace
Direct company coverage
Lundbeck Schizophrenia Drug Fails to Differentiate Itself from Conventional Therapies, Stocks Plunge
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Oct 2018 07:00
- Source
- BioSpace